{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:13:16Z","timestamp":1761520396893,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clcc.2023.08.005","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T02:45:44Z","timestamp":1691721944000},"page":"450-456.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin"],"prefix":"10.1016","volume":"22","author":[{"given":"Filippo","family":"Ghelardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Pannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Guaglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Mazzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Nasca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Leoncini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Sabella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella Francesca","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca Rosa","family":"Lampis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Delfanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Nannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Intini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Baratti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2023.08.005_bib0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-9-71","article-title":"Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects","volume":"9","author":"Amini","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clcc.2023.08.005_bib0002","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2023.08.005_bib0003","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejso.2007.04.002","article-title":"Appendiceal neoplasms and pseudomyxoma peritonei: a population based study","volume":"34","author":"Smeenk","year":"2008","journal-title":"Eur J Surg Oncol EJSO"},{"key":"10.1016\/j.clcc.2023.08.005_bib0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment","volume":"47","author":"Govaerts","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clcc.2023.08.005_bib0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.027","article-title":"A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors","volume":"226","author":"Levine","year":"2018","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.clcc.2023.08.005_bib0006","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1245\/s10434-007-9691-2","article-title":"Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"15","author":"Baratti","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clcc.2023.08.005_bib0007","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with Pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2023.08.005_bib0008","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1245\/ASO.2004.07.002","article-title":"Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with Pseudomyxoma peritonei","volume":"11","author":"Deraco","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clcc.2023.08.005_bib0009","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12967-016-0877-x","article-title":"GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study","volume":"14","author":"Pietrantonio","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.clcc.2023.08.005_bib0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/SLA.0b013e3182602ad2","article-title":"Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy","volume":"256","author":"Chua","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.clcc.2023.08.005_bib0011","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.3748\/wjg.v12.i38.6124","article-title":"Management of pseudomyxoma peritonei","volume":"12","author":"Qu","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clcc.2023.08.005_bib0012","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/cncr.24715","article-title":"Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience","volume":"116","author":"Shapiro","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2023.08.005_bib0013","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1634\/theoncologist.2014-0106","article-title":"FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma","volume":"19","author":"Pietrantonio","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2023.08.005_bib0014","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s10147-019-01592-x","article-title":"Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei","volume":"25","author":"Hiraide","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clcc.2023.08.005_bib0015","first-page":"e179","article-title":"Metronomic capecitabine with cyclophosphamide regimen in unresectable or relapsed pseudomyxoma peritonei","volume":"18","author":"Raimondi","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2023.08.005_bib0016","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bjc.6604522","article-title":"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei","volume":"99","author":"Farquharson","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2023.08.005_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.16161","article-title":"Efficacy of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma: a randomized crossover trial","volume":"6","author":"Shen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clcc.2023.08.005_bib0018","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1158\/1078-0432.CCR-21-0982","article-title":"Organoid platform in preclinical investigation of personalized immunotherapy efficacy in appendiceal cancer: feasibility study","volume":"27","author":"Forsythe","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2023.08.005_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003109","article-title":"Peptide vaccine targeting mutated GNAS\u00a0: a potential novel treatment for pseudomyxoma peritonei","volume":"9","author":"Flatmark","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002823000786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002823000786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:09:27Z","timestamp":1761520167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002823000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1533002823000786"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2023.08.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2023.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}